RVU120 Rollover Study

Participants may continue treatment until loss of clinical benefit as judged by the investigator, unacceptable toxicity, start of subsequent anticancer therapy, or until any other criterion for withdrawal from the treatment or the study is met.

Inclusion criteria

• The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles.
• The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the criteria set out in the parent study protocol and according to the judgment of the investigator and sponsor.
• The participant does not have access to commercially available comparator anticancer therapy.
• Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• The participant signed the rollover study ICF prior to any study-related procedure or study data collection.
• The participant agrees not to donate blood during study participation and until 28 weeks (~6.5 months) after the last dose.
• The investigator considers the participant to be eligible for participation in the rollover study.

Exclusion criteria

• Presence of toxicity that cannot be adequately managed.
• Concurrent participation in any therapeutic clinical study other than the parent study.